Systematic chemical modification of a scaffold compound led to discovery of new ligands with high affinity and selectivity for the CB2 cannabinoid receptor.
Medicinal chemists, cannabinoid pharmacologists, and drug discovery researchers.
High CB2 selectivityNew pyrazolopyridine derivatives showed high affinity and selectivity for CB2 over CB1 receptor
What the researchers found
Through systematic substitution pattern modification of 7-hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide, researchers identified new compounds with high CB2 receptor affinity and selectivity, functioning as either agonists or inverse agonists.
Why it matters
Selective CB2 receptor drugs could treat inflammation and pain without psychoactive effects. Discovering new selective ligands expands the toolkit for cannabinoid drug development.
The numbers in context
The 7-hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide scaffold produced derivatives acting as CB2 agonists or inverse agonists with high selectivity.
How the study worked
Medicinal chemistry study systematically modifying a chemical scaffold to optimize CB2 receptor affinity and selectivity.
Who was studied
Chemical compounds assessed for CB2 receptor affinity and selectivity in vitro.
What this study cannot tell us
In vitro receptor binding does not guarantee in vivo efficacy; ADMET properties need assessment; translation from binding studies to therapeutic candidates is a long process.
How to read the evidence
Medicinal chemistry with in vitro receptor binding data; early-stage drug discovery evidence.
When this study was published
Recent medicinal chemistry advance in CB2-targeted drug development.
The bigger picture
CB2-selective compounds represent one of the most promising areas of cannabinoid drug development, potentially delivering anti-inflammatory and analgesic effects without the psychoactive profile of THC.
Replication
Builds on prior scaffold identification; part of ongoing CB2 drug discovery program.
Funding
Not specified
Conflicts of interest
Not specified
Questions still open
- Which derivatives have the best drug-like properties?
- Do agonists and inverse agonists have different therapeutic applications?
- How do these compare to existing CB2 drug candidates?
Read the original research
Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 Receptor.
Molecules (Basel, Switzerland), 28(13)
Citation
Mugnaini, Claudia; Kostrzewa, Magdalena; Casini, Marta; Kumar, Poulami; Catallo, Valeria; Allarà, Marco; Guastaferro, Laura; Brizzi, Antonella; Paolino, Marco; Tafi, Andrea; Kapatais, Christelos; Giorgi, Gianluca; Vacondio, Federica; Mor, Marco; Corelli, Federico; Ligresti, Alessia. (2023). Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-b]pyridine-6-carboxamide Scaffold Enabled the Discovery of New Ligands with High Affinity and Selectivity for the Cannabinoid Type 2 Receptor.. Molecules (Basel, Switzerland), 28(13). https://doi.org/10.3390/molecules28134958